Rockwell Medical Technologies (NASDAQ: RMTI) reported Q2 EPS of ($0.14), $0.04 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $13.05 million.

Q2 2017 Financial Highlights

• Sales were $13.2 million compared to $13.4 in Q2 2016.
• Gross profit was $1.5 million, unchanged compared to Q2 2016.
• SG&A expense was $6.5 million compared $5.0 million in Q2 2016.
• R&D expense was $1.7 million compared to $2.1 million in Q2 2016.
• Net loss was $7.1 million or ($0.14) per share compared to a $5.4 million loss or ($0.11) per share in Q2 2016.
• Cash and investments were $43.2 million as of June 30, 2017.
• Net working capital was $56.1 million as of June 30, 2017.

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.